1Chemotherapy in non-small cell lung cancer: a recta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group [ J ] . BMJ,1995, 311: 899-909.
2DELBALDO C, MICHIELS S, SYZ N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis [ J ] . JAMA,2004, 292: 470-484.
3SCHILLER J H, HARRINGTON D, BELANI C P, et al. Comparison of four chemotherapy regimens for advanced non- small-cell lung cancer [ J ] . N Engl J Med, 2002, 346: 92- 98.
4SCAGLIOTTI G V, PARIKH P, VON PAWEL J, etal. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [ J ] . J Clin Oncol, 2008, 26:3543-3551.
5MOK T S, WU Y L, THONGPRASERT S, ct al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [ J ] . N Engl J Med, 2009, 361: 947-957.
6HAN J Y, PARK K, KIM S W, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung [ J ] . J Clin Oncol, 2012, 30:1122-1128.
7MITSUDOMI T, MORITA S, YATABE Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small- cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [ J ] . Lancet Oncol, 2010, 11: 121-128.
8MAEMONDO M, INOUE A, KOBAYASHI K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [ J ] . N Engl J Med, 2010, 362: 2380-2388.
9ZHOU C, WU Y L, CHEN G, et al. Erlotinib versus ehemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multieentre, open-label, randomised, phase 3 study [ J ] . Lancet Oneol, 2011, 12: 735-742.
10ROSELL R, CARCERENY E, GERVAIS R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-eell lung cancer (EURTAC): a multieentre, open- label, randomised phase 3 trial [ J ]. Lancet Oneol, 2012, 13: 239-246.
7Skopinska-Rozewska E, Malinowski M, Wasiutynski A, et al. The influence of Rhodiola quad-ifida 50% hydro-alcoholic extract and salidroside on tumor-induced angiogenesis in mice[J]. Pol J Vet Sci,2008,11(2) :97.
8Johnstone R. W. , A. A. RuefliS. W. Lowe, Apoptosis: A link between cancer genetics and chemotherapy[J]. Cell, 2002,108(2) : 153.
9Hasturk S, Hatabay N, Ece F, et al. Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer. Am J Clin Oncol, 2009, 32(3):280-285.
10Azzoli CG, Baker S, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 2009, 27(36): 6251-6266.
